HERTHENA-Lung01: A randomized phase 2 study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC Meeting Abstract
| Authors: | Janne, P. A.; Johnson, M. L.; Goto, Y.; Yang, J. C. H.; Vigliotti, M.; Dong, Q.; Qiu, Y.; Yu, C.; Yu, H. A. |
| Abstract Title: | HERTHENA-Lung01: A randomized phase 2 study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120307050 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.TPS9139 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS9139 -- Source: Wos |
